

Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer

Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that Henrik Damkjær Simonsen has been appointed Chief Financial Officer, as of April 1, 2023. He succeeds Peter Åkerlund who has been acting CFO since November 16 of this year.

Henrik Damkjær Simonsen has more than 30 years of experience from various senior roles in the life science industry, both on the banking and on the business side. He comes from a position as Finance Director at SAGA Diagnostics AB and has previously worked as CFO at Nuevolution AB and as Head of Life Science, Corporate Finance at SEB, among others.

"I am very much looking forward to welcoming Henrik to the team at Iconovo. His comprehensive experience from the capital markets in general and life science companies in particular, is an excellent fit as we work to establish Iconovo as a global leader in inhalation treatments," says Johan Wäborg, CEO of Iconovo.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2024. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

Attachments

[Iconovo appoints Henrik Damkjær Simonsen as Chief Financial Officer](#)